{"entity":{"id":"nct06659705","kind":"trial","name":"Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)","aka":["INDIGO-FAPI"],"tldr":"A phase 2 trial in pancreatic cancer, run by Institut Curie, now recruiting.","summary":"Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) is a phase 2, interventional study registered as NCT06659705 by Institut Curie, with a registry enrolment figure of 35 participants, started 2025-12-02 and due to reach its primary completion in 2029-08-04. Interventions recorded: 68Ga-FAPI-46 for PET / CT scan. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC). Primary outcome: EFS: Event Free Survival. Sites: France. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06659705","url":"https://clinicaltrials.gov/study/NCT06659705"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06659705","phase":"2","setting":"Cutting Edge Imaging for Earlier Pancreatic Cancer Diagnosis: Evaluation of Positron Emission Tomography (PET) With the Fibroblast Activation Protein Inhibitor (FAPI)","sponsor":"Institut Curie","enrolled":35,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06659705/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}